Publications by authors named "Tom Vink"

Claim this Profile
R
Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.
Pekka Kallunki, Florence Sotty, Katarina Willén, Michal Lubas, Laurent David, Tom Vink

NPJ Parkinsons Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.
Mario Losen, Aran F Labrijn, Vivianne H van Kranen-Mastenbroek, Maarten L Janmaat, Krista G Haanstra, Tom Vink

Sci Rep· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
Patrick J Engelberts, Marleen Voorhorst, Janine Schuurman, Tom van Meerten, Joost M Bakker, Tom Vink

J Immunol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.
Bart E C G de Goeij, Tom Vink, Hendrik Ten Napel, Esther C W Breij, David Satijn

Mol Cancer Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
Bart E C G de Goeij, Matthias Peipp, Simone de Haij, Edward N van den Brink, Christian Kellner, Tom Vink

MAbs· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simple, robust and highly efficient transient expression system for producing antibodies.
Tom Vink, Maroeska Oudshoorn-Dickmann, Marcel Roza, Jelte-Jan Reitsma, Rob N de Jong

Methods· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG.
Rebecca J Rose, Patrick H C van Berkel, Ewald T J van den Bremer, Aran F Labrijn, Tom Vink

MAbs· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crosstalk between human IgG isotypes and murine effector cells.
Marije B Overdijk, Sandra Verploegen, Antonio Ortiz Buijsse, Tom Vink, Jeanette H W Leusen

J Immunol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Marije B Overdijk, Sandra Verploegen, Jeroen H van den Brakel, Jeroen J Lammerts van Bueren, Tom Vink

J Immunol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.
Aran F Labrijn, Theo Rispens, Joyce Meesters, Rebecca J Rose, Tamara H den Bleker, Tom Vink

J Immunol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
Michel de Weers, Yu-Tzu Tai, Michael S van der Veer, Joost M Bakker, Tom Vink

J Immunol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system.
Patrick H C van Berkel, Jolanda Gerritsen, Edwin van Voskuilen, Gerrard Perdok, Tom Vink

Biotechnol Bioeng· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG.
Patrick H C van Berkel, Jolanda Gerritsen, Gerrard Perdok, Jesper Valbjørn, Tom Vink

Biotechnol Prog· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.
Frank J Beurskens, Sigrid R Ruuls, Patrick J Engelberts, Tom Vink, Wendy J Mackus

Blood· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Matthias Peipp, Jeroen J Lammerts van Bueren, Tanja Schneider-Merck, Wim W K Bleeker, Michael Dechant, Tom Vink

Blood· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.
Marijn van der Neut Kolfschoten, Janine Schuurman, Mario Losen, Wim K Bleeker, Pilar Martínez-Martínez, Tom Vink

Science· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.
Jessica L Teeling, Wendy J M Mackus, Luus J J M Wiegman, Jeroen H N van den Brakel, Stephen A Beers, Tom Vink

J Immunol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanocortin system and eating disorders.
Roger A H Adan, Jacquelien J G Hillebrand, Corine De Rijke, Wouter Nijenhuis, Tom Vink

Ann N Y Acad Sci· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis